

Contents

Part A	The context and terms of reference of this report	
1	Historical background	1
2	The terms of the RSPCA exception to the injunction and basis for the Society's review	2
3	Description of the material available to the RAD	4
3.1	Imutran documents supplied by Uncaged	4
3.2	The Uncaged report – Diaries of Despair	4
3.3	Material provided by Imutran	5
3.4	Other information	5
4	Brief description of the research	6
5	Method of Review and issues of confidentiality	6
Part B	RAD analysis of the documents downloaded from the Uncaged website in relation to xenotransplantation in general and the ASPA in particular	
1	Introduction	9
2	Xenotransplantation as an issue of public concern	9
2.1	Controversy and public consultations	9
2.2	Decisions on ethical acceptability of xenotransplantation as a technology	10
2.3	How research progress is presented to the public	12
3	Welfare implications of the acquisition, importation and confinement of baboons and macaques	13
3.1	Source of animals	13
3.1.1	Home Office authorisation of overseas sources	14
3.1.2	An ethical dilemma regarding 'third countries'	14
3.1.3	A South African breeding centre	15
3.2	Transporting and importing primates	16
3.2.1	Disparity in numbers imported and used	17
3.2.2	Deaths in transit	17
3.3	Conclusions	18
4	Implementation of ASPA and the adequacy of the legislation	18
4.1	Key questions	19
4.2	The project licences	21

4.3	The research and the APC	21
4.4	Inter-relation between the HO and the APC and UKXIRA	25
4.5	The cost-benefit assessment as a concept	26
5	The cost-benefit assessment: costs to animals	28
5.1	The criticism of Imutran by Uncaged	28
5.2	RAD assessment of the harms suffered	29
5.2.1	Suffering due to acquisition and transport	30
5.2.2	Suffering due to confinement in captivity	30
5.2.3	Suffering due to the procedures and their effects	33
5.3	Costs: conclusions	35
6	The cost-benefit assessment: potential benefits	36
6.1	Xenotransplantation as a technology	37
6.2	The Imutran projects	37
7	The cost-benefit assessment – was the research justified?	39
8	Other issues relating to the study reports	39
8.1	Humane end-points and the inviolable termination condition	39
8.2	Monitoring	41
8.2.1	Monitoring adverse effects	41
8.2.2	Frequency of monitoring	42
8.3	End-points and monitoring: some key questions	43
9	Surgical procedures and post-operative care	44
9.1	Errors in surgical procedures	45
9.1.1	Surgical swab	45
9.1.2	Frozen kidney	45
10	Matters relating to HLS	45
10.1	Background material	46
10.2	GLP non-compliance and errors in data recording	47
10.2.1	GLP non-compliance	47
10.2.2	Errors in data recording	48
10.3	Errors with potential animal welfare consequences	49
10.3.1	An error in dose level and in sampling time	49
10.3.2	Re-use, an infringement of ASPA	50
10.4	Summary points	50
11	Primates as a biohazard	51
12	Summary of Main Concerns	51
12.1	The ASPA: implementation and compliance	51
12.1.1	Assessing costs and benefits	53
12.1.2	Humane end-points and monitoring of animals	53
12.1.3	Severity bandings	54
12.1.4	Retrospective review	55
12.1.5	Surgical technique	55

12.1.6	GLP and other ‘errors’	56
12.1.7	Confidentiality between APC, UKXIRA and the HO	57
12.2	Primate issues	57
12.2.1	Primate acquisition and transport	57
12.2.2	Primate husbandry	58
12.2.3	Training of primates and of staff to work with them	59
12.3	Xenotransplantation as a technology	59
13	Concluding remarks	60
	Appendix A	63
	References	65